CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes
The European Union's medicines regulator did not mention Eisai and Biogen's Alzheimer's drug in its notes and recommendations on Friday.
Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)
Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript)
Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today
Biogen Inc. (BIIB) reachead $219.40 at the closing of the latest trading day, reflecting a +0.04% change compared to its last close.
Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know
Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close.
Three-Stock Lunch: Biogen, DocuSign & Gap
Gina Sanchez, Lido Advisors chief market strategist, joins 'Power Lunch' to discuss stock plays for three stocks, including Biogen, DocuSign and Gap.
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
If you're looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ: IBB ) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U...
Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript)
Biogen Inc. (NASDAQ:BIIB ) TD Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Michael McDonnell - Chief Financial Officer Alisha Alaimo - President, Hea...
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
Biogen's earnings declined significantly in 2023. Management's financial guidance for 2024 is not very positive.
EU medicines regulator backs Biogen's ALS drug
Europe's medicines regulator said on Friday that it has recommended granting a marketing authorization for Biogen's drug for a type of neurological disease known as amyotrophic lateral sclerosis (A...
Biogen receives subpoena from DOJ on business operations in foreign countries
Biogen has received a subpoena from the U.S. Department of Justice seeking information relating to the company's business operations in several foreign countries, the drugmaker disclosed in a filin...
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.
Here's What Key Metrics Tell Us About Biogen Inc. (BIIB) Q4 Earnings
The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Stree...
Biogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $2.95 per share, missing the Zacks Consensus Estimate of $3.16 per share. This compares to earnings of $4.05 per share a year ago.
Related Companies